Abstract
The synthesis, evaluation, and structure-activity relationships of a class of γ-lactam 1,3-diaminopropan-2-ol transition-state isostere inhibitors of BACE are discussed. Two strategies for optimizing lead compound 1a are presented. Reducing the overall size of the inhibitors resulted in the identification of γ-lactam 1i, whereas the introduction of conformational constraint on the prime-side of the inhibitor generated compounds such as the 3-hydroxypyrrolidine inhibitor 28n. The full in vivo profile of 1i in rats and 28n in Tg 2576 mice is presented.
Copyright © 2011 Elsevier Ltd. All rights reserved.
MeSH terms
-
Alzheimer Disease / drug therapy
-
Alzheimer Disease / enzymology
-
Amyloid Precursor Protein Secretases / antagonists & inhibitors*
-
Amyloid Precursor Protein Secretases / metabolism*
-
Animals
-
Crystallography, X-Ray
-
Drug Design
-
Enzyme Inhibitors / chemical synthesis
-
Enzyme Inhibitors / chemistry*
-
Enzyme Inhibitors / pharmacokinetics
-
Enzyme Inhibitors / pharmacology*
-
Lactams / chemical synthesis
-
Lactams / chemistry*
-
Lactams / pharmacokinetics
-
Lactams / pharmacology*
-
Mice
-
Models, Molecular
-
Rats
-
Structure-Activity Relationship
Substances
-
Enzyme Inhibitors
-
Lactams
-
Amyloid Precursor Protein Secretases